Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well
tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and
psychosis. The secondary objectives are to determine whether ACP-103 will ameliorate
psychosis in patients with Parkinson's disease and whether ACP-103 is safe in Parkinson's
disease patients taking multiple anti-parkinsonian medications.